HUTCHMED (China) Limited

NasdaqGS:HCM Stock Report

Market Cap: US$2.1b

HUTCHMED (China) Future Growth

Future criteria checks 1/6

HUTCHMED (China)'s earnings are forecast to decline at 67.4% per annum while its annual revenue is expected to grow at 13.6% per year. EPS is expected to decline by 59.1% per annum. Return on equity is forecast to be 6.7% in 3 years.

Key information

-67.4%

Earnings growth rate

-59.11%

EPS growth rate

Pharmaceuticals earnings growth14.4%
Revenue growth rate13.6%
Future return on equity6.70%
Analyst coverage

Good

Last updated06 Jul 2026

Recent future growth updates

Recent updates

Seeking Alpha • Jan 30

Despite A Promising Future For Hutchmed, We Have Concerns About Development Of The Share Price (Rating Downgrade)

Summary Despite a 32% drop in share price, HCM's oncology treatments show potential for growth, with expected revenue increases driving earnings and share price up. HCM's sale of a 45% stake in Shanghai Hutchison Pharmaceuticals for $608 million will fund internal product development, enhancing its market position. The current share price of $13.56 suggests an attractive valuation with a FWD P/E of 18.1 and an EV/Sales of 2.44. However, concerns over poor performance of the share prices of Li family-controlled companies led us to downgrade HCM from Buy to Hold. Read the full article on Seeking Alpha
Seeking Alpha • Aug 09

Hutchmed Growing Sales By 64% In H1 2024

Summary Share price up nearly 20% since our previous Buy call. Approval of the colon cancer drug FRUZAQLA by the U.S. FDA was a game-changer to their growth in sales. We expect continued growth in sales of oncology products from the approval of FRUZAQLA in the E.U. and Japan. Read the full article on Seeking Alpha
Seeking Alpha • Mar 20

Hutchmed Is Turning Profitable

Summary Hutchmed China is a biopharmaceutical company with a market capitalization of $3 billion. HCM's total revenue doubled to $838 million in 2023, driven by sales of the cancer drug FRUZAQLA. The company delivered a profit of $100.8 million in 2023 and has a strong cash position of over $880 million. FDA approval at the end of last year, and hopefully similar approvals from the EU and Japan will be a gamechanger for HCM. Read the full article on Seeking Alpha
Seeking Alpha • Oct 10

Hutchmed begins dosing in phase 2/3 trial of sovleplenib for red blood cell disorder

Hutchmed (China) (NASDAQ:HCM) said it began dosing in a phase 2/3 trial of sovleplenib in adult patients with warm antibody autoimmune hemolytic anemia in China. Warm autoimmune hemolytic anemia is an autoimmune disorder characterized by premature destruction of healthy red blood cells (hemolysis). The main goal of the phase 2 stage is evaluating the safety and preliminary efficacy of sovleplenib and main goal is the proportion of patients with overall hemoglobin (Hb) response by week 24. If results are positive, phase 3 stage will be started wherein the main goal would be the proportion of patients who achieve a durable Hb response by week 24, the company said in an Oct. 10 press release. The company expects to enroll 110 patients. Hutchmed noted that it currently retains all rights to sovleplenib worldwide. The drug is also being studied in immune thrombocytopenia, indolent non-Hodgkin's lymphoma and multiple subtypes of B-cell malignancies in China, U.S. and Europe.

Earnings and Revenue Growth Forecasts

NasdaqGS:HCM - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202882391486317
12/31/202773265245122
12/31/202663644113422
12/31/2025549457-89-65N/A
9/30/2025575462-74-49N/A
6/30/2025602467-60-33N/A
3/31/2025616252-39-16N/A
12/31/202463038-170N/A
9/30/2024621-2-41-23N/A
6/30/2024611-42-65-47N/A
3/31/2024724296186N/A
12/31/2023838101187219N/A
9/30/20237983695133N/A
6/30/2023757-29248N/A
3/31/2023592-195-151-110N/A
12/31/2022426-361-305-269N/A
9/30/2022414-308-276-246N/A
6/30/2022401-255-246-223N/A
3/31/2022376-235-245-227N/A
12/31/2021356-195-221-204N/A
9/30/2021317-187-169-155N/A
6/30/2021279-178-118-105N/A
3/31/2021258-151-95-83N/A
12/31/2020228-126-70-62N/A
9/30/2020221-117-72-63N/A
6/30/2020209-110-88-79N/A
3/31/2020204-102-63-54N/A
12/31/2019205-106-89-81N/A
9/30/2019205-93N/A-77N/A
6/30/2019214-87N/A-44N/A
3/31/2019214-83N/A-31N/A
12/31/2018214-75N/A-33N/A
9/30/2018218-72N/A-33N/A
6/30/2018217-61N/A-47N/A
3/31/2018230-39N/A-49N/A
12/31/2017241-27N/A-9N/A
9/30/2017240-7N/A-4N/A
6/30/201723813N/A1N/A
3/31/201722712N/A-4N/A
12/31/201621612N/A-10N/A
9/30/201620038N/A2N/A
6/30/2016200-8N/A-1N/A
3/31/2016189-22N/A-5N/A
12/31/2015178-35N/A-9N/A
9/30/2015168-80N/A-11N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HCM's earnings are forecast to decline over the next 3 years (-67.4% per year).

Earnings vs Market: HCM's earnings are forecast to decline over the next 3 years (-67.4% per year).

High Growth Earnings: HCM's earnings are forecast to decline over the next 3 years.

Revenue vs Market: HCM's revenue (13.6% per year) is forecast to grow faster than the US market (12.7% per year).

High Growth Revenue: HCM's revenue (13.6% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: HCM's Return on Equity is forecast to be low in 3 years time (6.7%).

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/06 05:46
End of Day Share Price 2026/07/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

HUTCHMED (China) Limited is covered by 53 analysts. 22 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alec StranahanBofA Global Research
John NewmanCanaccord Genuity
Adam McCarterCavendish